Furthermore, administration of IFN-γ to the patients with MS patients exacerbated the disease, whereas administration of neutralizing antibodies against IFN-γ had therapeutically beneficial effects (Kostic et al., 2015; Raphael et al., 2015). This evidence concerns the gene IFNG and myeloid sarcoma.